Odense University Hospital

Running trials

• Not yet recruiting

  BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

  NCT07474961· Phase 4· Anne Louise Tølbøll Sørensen· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· University of Aarhus· Source

• Not yet recruiting

  Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study

  NCT07634263· Odense University Hospital· Source

• Not yet recruiting

  Home-based Exercise for Improving Health-related Quality of Life in Systemic Sclerosis

  NCT07840430· University of Aarhus· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial

  NCT07442357· Copenhagen University Hospital, Rigshospitalet· Source

• Not yet recruiting

  Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies

  NCT07878208· Odense University Hospital· Source

• Recruiting

  DAN-RELEASE - Reconsidering Long-Term Aspirin in the Elderly Patients With Stable Ischemic Heart Disease

  NCT07795398· Phase 4· Odense University Hospital· Source

• Recruiting

  A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

  NCT01491815· Phase 4· Karolinska Institutet· Source

• Recruiting

  A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors

  2025-523665-24-00· Phase 1· Novartis Pharma AG· Source

• Not yet recruiting

  Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE

  NCT07870681· Phase 2/3· Oslo University Hospital· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Ole Schmeltz Søgaard· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Not yet recruiting

  Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)

  2025-523414-89-00· Phase 2· Steno Diabetes Center Copenhagen· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

  NCT07757412· Phase 2· Odense University Hospital· Source

• Not yet recruiting

  Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation

  NCT07727135· Herlev and Gentofte Hospital· Source

• Recruiting

  Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer

  NCT07432802· Aarhus University Hospital· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source

• Not yet recruiting

  Family TIME: A Family-focused Nursing Intervention for Adults Receiving Haemodialysis and Their Families

  NCT07801937· University of Southern Denmark· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)

  NCT07646977· Odense University Hospital· Source

• Recruiting

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Phase 1· Janssen Cilag International· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· Phase 3· AstraZeneca· Source

• Not yet recruiting

  BEAT Fatigue

  2024-519268-41-00· Phase 4· Odense University Hospital· Source

• Recruiting

  Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?

  NCT07733505· Phase 1· Odense University Hospital· Source

• Not yet recruiting

  MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)

  NCT07635108· Odense University Hospital· Source

• Not yet recruiting

  The MAYA2 trial

  2025-521941-25-00· Phase 2· Odense University Hospital· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors

  2025-521911-38-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Vascular Complications After Kidney Transplantation

  NCT07531966· University of Aarhus· Source

• Recruiting

  A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors

  2025-521702-18-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial

  NCT07478003· Phase 3· Thomas Engstrom· Source

• Recruiting

  Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

  NCT07481175· Phase 1· Thomas Aagaard Rasmussen· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)

  NCT07511283· Odense University Hospital· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study

  2025-522338-30-00· Phase 2· Eli Lilly & Co.· Source

• Enrolling by invitation

  Women With Previous GDM and the Effects of HIIT.

  NCT07566845· Odense University Hospital· Source

• Recruiting

  A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma

  2025-521205-41-00· Phase 2· Aalborg University Hospital· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

Showing 50 of 371.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers27 recruiting
• Colorectal cancer20 recruiting
• Lung cancer18 recruiting
• Crohn's disease10 recruiting
• Heart failure10 recruiting
• Prostate cancer10 recruiting
• Coronary artery disease9 recruiting
• Multiple myeloma9 recruiting
• Acute myeloid leukaemia8 recruiting
• Atrial fibrillation8 recruiting
• Chronic lymphocytic leukaemia8 recruiting
• Endometrial cancer8 recruiting
• Acute lymphoblastic leukaemia7 recruiting
• Ovarian cancer7 recruiting
• Chronic kidney disease6 recruiting
• Pancreatic cancer6 recruiting
• Stroke6 recruiting
• Ulcerative colitis6 recruiting
• Bronchiectasis5 recruiting
• Metastatic breast cancer5 recruiting
• Type 1 diabetes5 recruiting
• Aortic stenosis4 recruiting
• Bladder cancer4 recruiting
• Cervical cancer4 recruiting
• Dilated cardiomyopathy4 recruiting
• High blood pressure4 recruiting
• Osteoporosis4 recruiting
• Rheumatoid arthritis4 recruiting
• Sarcoidosis4 recruiting
• Type 2 diabetes4 recruiting
• Follicular lymphoma3 recruiting
• Glioblastoma3 recruiting
• Kidney cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Chronic myeloid leukaemia2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• COPD2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Familial hypercholesterolaemia2 recruiting
• HIV2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Mantle cell lymphoma2 recruiting
• Multiple sclerosis2 recruiting
• Obesity2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Triple-negative breast cancer2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Ankylosing spondylitis1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Epilepsy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glaucoma1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis B1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Liver cirrhosis1 recruiting
• Lyme disease1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Parkinson disease1 recruiting
• Polycystic ovary syndrome1 recruiting
• Sarcoma1 recruiting
• Thalassaemia1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Active, not recruiting

  Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

  2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source

• Recruiting

  A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  NCT06747949· Phase 3· Amgen· Source

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

  NCT06613009· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  Melatonin fOr CHronic bAck Pain (The MOCHA Trial)

  NCT06476392· Phase 3· Odense University Hospital· Source

• Completed

  ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

  2024-514111-10-00· Phase 4· Rigshospitalet· Source

• Recruiting

  Effect Camostat for Kidney Protection in Chronic Kidney Disease

  NCT06794593· Phase 2· Odense University Hospital· Source

• Terminated

  Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents

  NCT06718179· Phase 4· Odense University Hospital· Source

• Completed

  Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease

  NCT06421597· Phase 2· Odense University Hospital· Source

• Completed

  Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID

  2023-506949-27-00· Phase 2· Odense University Hospital· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)

  2023-506550-20-00· Phase 2/3· Odense University Hospital· Source

• Recruiting

  A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

  NCT06311682· Phase 3· LEO Pharma· Source

• Completed

  Strength Training Exercises to Minimise Late Effects of Childhood Leukaemia or Lymphoma Among Adolescents

  NCT06299722· Aalborg University· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source

• Completed

  Long-term Monitoring of Sleep with Ear-EEG in Patients with Chronic Pain

  NCT06368531· Odense University Hospital· Source

• Completed

  A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  2022-502457-34-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

  NCT06169397· Phase 2· Xentria, Inc.· Source

• Completed

  A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

  NCT05901831· Phase 3· Bayer· Source

• Completed

  GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

  2022-502453-33-00· Phase 2· Genmab A/S· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Completed

  A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo and its safety and tolerability in participants 18 to 75 years of age with dyslipidemia

  2023-506197-12-00· Phase 2· Astrazeneca AB· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Janssen-Cilag Ltd.· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Genmab A/S· Source

• Completed

  A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

  2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Completed

  Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD

  2023-505053-40-00· Phase 2· Lillebaelt Hospital· Source

• Completed

  Observational Bronchoscopy Video Data Collection Study With Adult Patients

  NCT06465797· Ambu A/S· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  What Matters to Patients With Severe Hip or Knee Osteoarthritis?

  NCT05972525· Vejle Hospital· Source

• Completed

  Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors

  2022-502787-20-00· Phase 2· IO Biotech ApS· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  Senolytics to Improve Osteoporosis Therapy

  NCT06018467· Phase 2· Odense University Hospital· Source

• Completed

  The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial

  NCT05758779· Odense University Hospital· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the trial around the participant, known as decentralised, and hybrid clinical trials compared to standard clinical trials that take place in hospitals or in research centres, in patients with type 2 diabetes mellitus treated with Toujeo®, a drug to help manage blood sugar levels.

  2022-500449-26-00· Phase 4· University Medical Center Utrecht· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT06087289· Phase 1/2· Novakand Pharma AB· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  The DANish COronary DEcalcification (DANCODE) Trial

  NCT05500443· Odense University Hospital· Source

• Completed

  Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients

  NCT05575336· Biosistemak Institute for Health Systems Research· Source

• Completed

  Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis

  NCT05537025· Phase 1/2· Arrowhead Pharmaceuticals· Source

Showing 50 of 155.

Conditions

Diseases this institution publishes on or runs trials for.

• Type 2 diabetes78 works · 11 trials
• Crohn's disease31 works · 17 trials
• Multiple myeloma27 works · 37 trials
• Ulcerative colitis23 works · 11 trials
• Aortic stenosis18 works · 7 trials
• Aortic aneurysm16 works · 0 trials
• Diffuse large B-cell lymphoma10 works · 6 trials
• Coeliac disease6 works · 0 trials
• Fibromyalgia6 works · 0 trials
• Neuromyelitis optica (NMOSD)5 works · 0 trials
• Follicular lymphoma5 works · 7 trials
• Immune thrombocytopenia (ITP)4 works · 1 trial